Why the 2019 @BLS_gov Jobs report is a red flag for American #healthcare: bls.gov/news.release/e…
A thread to explain 1. You may recall that in late December 2017, #healthcare jobs overtook retail to become #1 for the first time in US history
@BLS_gov 2. Since that time, the US has added ~1 million more #healthcare jobs, >50,000 more in 2019 than 2018. No sector grew more in 2019.
(NB Education + healthcare sum is ~90% healthcare related)
@BLS_gov@EricMorath@TheAmaraReport 4. Human capital, i.e. the workforce, is the #1 driver of costs of healthcare. In the US we now pay > $11,000 per person with the worst major outcomes of all 36 @OECD countries. There are no data to suggest that more labor support will improve outcomes. growthevidence.com/growth-comment…
@BLS_gov@EricMorath@TheAmaraReport@OECD 5. So this is a feed the (broken) beast model. Nothing is being done to address it; the job growth is just celebrated.
Whereas the UK (which has better outcomes at half the cost) undertook an in-depth review & is implementing many worthy strategies topol.hee.nhs.uk
Three new @NEJM reports on #H5N1 today 1. An overview by @MichaelGIsonMD and @DrJeanneM
"urgent need for vigilant surveillance of emerging mutations and assessment of the threat of human-to-human transmission"
2. Report of the 13-year-old Canadian girl who developed acute respiratory failure. Sequence of her H5N1 revealed 3 mutations that may be linked to higher virulence and adaptation to human cell binding
3. Review of 46 cases of mild H5N1 illness by CDC in 2024
We're learning how to control the immune response, like a rheostat, even in the brain. Implications for understanding the basis and potential treatment of autoimmune conditions like multiple sclerosis, #LongCovid, #MECFS, and brain cancer.
A brief review of 6 recent, important reports
in the new Ground Truths, open-access
Such as Programming T cells with brain-specific proteins and payloads
@ScienceMagazine science.org/doi/10.1126/sc…
Or peptide fragments of myelin basic protein that suppress the immune response @Nature nature.com/articles/s4158…
New @NEJM
A whopping (~90%) reduction of progression to Type 2 diabetes with tirzepatide (GLP-1 drug, dual receptor) vs placebo in a randomized trial of >2,500 participants with obesity, absolute reduction of 10/100 treated
In other GLP-1 new publications today
—Country-wide Sweden reduced hospitalizations for alcohol or substance abuse with these drugs jamanetwork.com/journals/jamap… @JAMAPsych
—Concerns about discontinuation jamanetwork.com/journals/jama/… @JAMA_current
Other new anti-obesity drugs in the pipeline, one that also increases energy expenditure
@NatureNV nature.com/articles/d4158…
A dedicated issue of @ScienceTM on #LongCovid
—Sex-specific differences, with perspective by @VirusesImmunity and @SilvaJ_C
—Insights for therapies @AndreaCoxMDPhD
—Deconvoluting "Osler's Web" @MichaelPelusoMD @DeeksSteven @DrMaureenHanson @SaydahSharon
—+RECOVER Trial, Lyme disease
An elegant @Nature study by @AkassoglouLab has illuminated our understanding of the role of fibrin (component of blood clots), #SARSCoV2, and brain inflammation in Covid and #LongCovid.
This discovery and more in the new Ground Truths podcast, with transcript, key figures (such as as the one below) and citations. Open-access. Link in my profile.
A clip from our conversation. Unknowingly, @AkassoglouLab was gearing up for understanding this complex pathophysiology for many years before Covid hit
For treatment, it's not just as simple as preventing fibrin clots. It's isolating the pro-inflammatory action of fibrin, targeted by the antibody
Covid and increased risk of major adverse cardiovascular events (MACE) 3-years out
2-fold increased for any severity of Covid
~4-fold increase for Covid requiring hospitalization
"a coronary artery disease equivalent"
interaction with non-O blood types
@uk_biobankahajournals.org/doi/10.1161/AT…
"A major finding from our analyses was that the risk
of MACE among the subset of hospitalized COVID-
19 cases without known CVD (ie, primary prevention
patients) was comparable to (or even slightly higher than) the risk in patients with CVD, PAD, or diabetes but without COVID-19."
"one of the first examples of a gene-pathogen exposure interaction for thrombotic events"
I think it's the first one documented, likely others to be unraveled